An interventional study of 0 ul of palonosetron and 1 ul of palonosetron in Blood Coagulation Disorder, sponsored by Seoul National University Bundang Hospital. Status unknown at 1 site in Korea, Republic of. Open to participants aged 20 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-15.
Sponsored by Seoul National University Bundang Hospital · Not applicable, Interventional, and Basic science
Palonosetron may alter whole blood coagulation. However, little is known about the dose-response relationships according to the blood concentration of palonosetron. The investigators therefore will perform the present study to measure the effect of palonosetron levels using thromboelastography.
503 studies on the registry are indexed under Hemostatic Disorders; 71 are open to participants now.
This study's planned enrollment of 12 is below the median of 51 across 253 interventional studies indexed under Hemostatic Disorders.
Browse Hemostatic Disorders studies →Seoul National University Bundang Hospital is the lead sponsor of 368 studies on the registry; 55 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Blood specimen which was added of 0 ul of palonosetron
Drug: 0 ul of palonosetron
Blood specimen which was added of 1 ul of palonosetron
Drug: 1 ul of palonosetron
Blood specimen which was added of 10 ul of palonosetron
Drug: 10 ul of palonosetron
Blood specimen which was added of 100 ul of palonosetron
Drug: 100 ul of palonosetron
Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (0 ul) using palonosetron
Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (1 ul) using palonosetron
Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (10 ul) using palonosetron
Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (100 ul) using palonosetron
Citrated Functional Fibrinogen
Provides clot strength based on fibrinogen contribution
Time frame: During the thromboelastography analysis/ an average of 1 hour
Citrated Kaolin
Normal thromboelastography
Time frame: During the thromboelastography analysis/ an average of 1 hour
Citrated Kaolin Heparinase
To assess the effect of heparin
Time frame: During the thromboelastography analysis/ an average of 1 hour
Citrated Rapid Thromboelastography
A quicker assessment of clot strength, without assessment of clot initiation
Time frame: During the thromboelastography analysis/ an average of 1 hour
Heparinized Kaloin Heprinase
To measure the platelet function
Time frame: During the thromboelastography analysis/ an average of 1 hour
Activator F
To elimitate the platelt function
Time frame: During the thromboelastography analysis/ an average of 1 hour
Adenosine diphosphate
To measure the drug effect
Time frame: During the thromboelastography analysis/ an average of 1 hour
Arachidonic acid
To measure the drug effect
Time frame: During the thromboelastography analysis/ an average of 1 hour
This study is status unknown, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Seoul National University Bundang Hospital